

Haematologica
HAEMATOL/2017/167080
Version 3

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib

Stein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, Vinko Tosevski, Krzysztof Warzocha, Claudia Dumrese, Augustin Ferrant, Tobias Gedde-Dahl, Andrzej Hellmann, Jeroen Janssen, Boris Labar, Alois Lang, Waleed Majeed, Georgi Mihaylov, Jesper Stentoft, Leif Stenke, Josef Thaler, Noortje Thielen, Gregor Verhoef, Jaroslava Voglova, Gert Ossenkoppele, Andreas Hochhaus, Henrik Hjorth-Hansen, Satu Mustjoki, Sieghart Sopper, Francis Giles, Kimmo Porkka, Dominik Wolf, and Bjørn Tore Gjertsen

Disclosures: ENEST1st was a Novartis sponsored study, and the PD/PK substudy 4 was supported by Novartis. FG, JJ, and BTG have received research support from Novartis. SM and KP have received honoraria from Bristol-Myers Squibb, Novartis, Ariad and Pfizer. DW was ad-board member and has received research support and speaker's honorary from Novartis. AH and GO have received research support from Ariad, Bristol-Myers Squibb, Pfizer and Novartis. JT have received research funding from AOP Orphan. DW was supported by the Österreichische Nationalbank (Jubiläumsfondsprojekt Nr. 14781) and SM by the Finnish Cancer Institute. HHjH received honoraria from Ariad and through the Nordic CML Study Group research support from Bristol-Myers Squibb, Novartis and Pfizer.

Contributions: FG and AH designed and conducted the ENEST1st clinical study. KW, AF, TG-D, AH, BL, AL, WM, GM, JS, LS, JT, NT, GV, JV, GO, HH-H, KP, DW and BTG collected and preserved primary material on site and shipped material to the lab of BTG for analysis. BTG, JS, SG, SEG, VT and CD conceived the experiential approach. SEG and VT performed all experiments, and BTG, JS, SG, SEG and VT analyzed the data. SEG, JS, SG and BTG wrote the manuscript. JJ, NT, SM, SS, KP, DW, FG, GO, SM contributed writing the manuscript.